Oncomeg OS

Megestrol Acetate Oral Suspension 40 mg/mL, available in 160 mg/4 mL concentration and 120 mL pack size. Schedule H prescription medication to be used strictly under registered medical practitioner supervision.

• Therapeutic Category

Composition Specifications

Product Overview

Active Ingredient: Megestrol Acetate 40 mg/mL.

Oncomeg OS is a pharmaceutical formulation of Megestrol Acetate categorized as an appetite stimulant and progestational agent, specifically indicated for patient care routines across institutional Oncology Centres.

Each mL of oral suspension contains Megestrol Acetate 40 mg/mL, delivering a total strength of 40 mg per 1 mL or 160 mg per 4 mL unit measure in 120 mL bottles.

— Approved Profile
/ Administration Route

Clinical Indications

Dosage & Usage

Indicated for the treatment of anorexia, cachexia, and unexplained weight loss in patients with AIDS. Approved for therapeutic intervention in oncological and immunocompromised clinical protocols.

Administer via oral route only. Bottle must be shaken well prior to administration. Specific dose and duration must be determined by the treating physician per approved prescribing information.

Notice regarding CKD: Usage for anorexia or unexplained weight loss in Chronic Kidney Disease (CKD) is considered off-label unless explicitly covered by local approved prescribing information.

+ Risk Assessment

Safety & Warnings

Contraindications & Warnings

Side Effects & Interactions

Special Populations

Contraindicated in patients with known hypersensitivity to Megestrol Acetate or excipients, and during pregnancy. Exercise caution in patients with thromboembolic history, adrenal insufficiency, Cushing syndrome, or diabetes.

Side effects include nausea, diarrhea, flatulence, rash, hypertension, fatigue, insomnia, abdominal pain, constipation, dry mouth, palpitations, anemia, and sexual dysfunction. Serious risks involve thromboembolism, adrenal insufficiency, and glucose intolerance.

Avoid during pregnancy. Lactation requires medical risk-benefit assessment. Use in pediatric, elderly, renal, or hepatic impaired populations must strictly follow physician judgment and approved product guidelines.

• Licensing Data
■ Product Care

Regulatory Credentials

Storage & Shelf Life

Manufactured by Hattersley Pharmaceuticals, Jalandhar, Punjab. Operating under Drug Licence numbers 20B-122916 and 21B-122917 with full GMP compliance. Schedule H drug to be dispensed under medical supervision.

Protect container from direct sunlight and store in a cool, dry place with cap tightly closed. Expiry date and shelf life details are stamped directly on the outer pack marking.

• Institutional Enquiries
+ Safety Desk

Product Enquiry

Report Adverse Events

Healthcare institutions and oncology centers can submit technical product enquiries, sample requests, or bulk purchasing requests using the medical enquiry form below.

Report adverse events to hattersleypharmaceuticals@gmail.com or call 8557001122, 7009872541, or 7814781002. Please include patient age, sex, onset date, batch/lot number, expiry date, dose duration, concomitant medications, and reporter details.

Serious events (death, life-threatening, hospitalization, disability, or birth defects) must be reported promptly to the company Pharmacovigilance Department and/or PvPI.